Xalkori

Overview

crizotinib

kinase inhibitor

• CYP3A4 substrate
• OCT2 substrate
• CYP3A4 inhibitor, moderate
• OCT2 inhibitor
• bradycardia
• hypokalemia
• myelosuppressive oncologic agent
• photosensitivity
• prolongs QT interval (known)

Contraindicated

• cisapride
Xalkori (crizotinib)

+

cisapride

1 interaction

Contraindicated

crizotinib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• domperidone
Xalkori (crizotinib)

+

domperidone

1 interaction

Contraindicated

crizotinib + domperidone

contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dronedarone
Xalkori (crizotinib)

+

dronedarone

1 interaction

Contraindicated

crizotinib + dronedarone

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• eliglustat
Xalkori (crizotinib)

+

eliglustat

1 interaction

Contraindicated

crizotinib + eliglustat

CYP2D6 EM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, use alternative or monitor ECG, HR, BP, electrolytes; decr. eliglustat dose to 84 mg qd; CYP2D6 IM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, avoid combo; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, bradycardia, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• flibanserin
Xalkori (crizotinib)

+

flibanserin

1 interaction

Contraindicated

crizotinib + flibanserin

contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects (hepatic metab. inhibited)

• levoketoconazole
Xalkori (crizotinib)

+

levoketoconazole

1 interaction

Contraindicated

crizotinib + levoketoconazole

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, renal transport inhibited, additive effects)

• lomitapide
Xalkori (crizotinib)

+

lomitapide

1 interaction

Contraindicated

crizotinib + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of adverse effects (hepatic metab. inhibited)

• pimozide
Xalkori (crizotinib)

+

pimozide

1 interaction

Contraindicated

crizotinib + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• posaconazole
Xalkori (crizotinib)

+

posaconazole

1 interaction

Contraindicated

crizotinib + posaconazole

contraindicated: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, hypokalemia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• thioridazine
Xalkori (crizotinib)

+

thioridazine

1 interaction

Contraindicated

crizotinib + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• acebutolol
Xalkori (crizotinib)

+

acebutolol

1 interaction

Avoid/Use Alternative

crizotinib + acebutolol

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• adagrasib
Xalkori (crizotinib)

+

adagrasib

1 interaction

Avoid/Use Alternative

crizotinib + adagrasib

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• adenosine
Xalkori (crizotinib)

+

adenosine

1 interaction

Avoid/Use Alternative

crizotinib + adenosine

use alternative or monitor HR, BP: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

• albuterol
Xalkori (crizotinib)

+

albuterol

1 interaction

Avoid/Use Alternative

crizotinib + albuterol

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Xalkori (crizotinib)

+

albuterol inhaled

1 interaction

Avoid/Use Alternative

crizotinib + albuterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• alectinib
Xalkori (crizotinib)

+

alectinib

1 interaction

Avoid/Use Alternative

crizotinib + alectinib

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• alfentanil
Xalkori (crizotinib)

+

alfentanil

1 interaction

Avoid/Use Alternative

crizotinib + alfentanil

use alternative or monitor HR, BP, resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• alfuzosin
Xalkori (crizotinib)

+

alfuzosin

1 interaction

Avoid/Use Alternative

crizotinib + alfuzosin

use alternative or monitor BP, ECG, electrolytes: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited, additive effects)

• alprazolam
Xalkori (crizotinib)

+

alprazolam

1 interaction

Avoid/Use Alternative

crizotinib + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• aminolevulinic acid topical
Xalkori (crizotinib)

+

aminolevulinic acid topical

1 interaction

Avoid/Use Alternative

crizotinib + aminolevulinic acid topical

avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)

• amiodarone
Xalkori (crizotinib)

+

amiodarone

1 interaction

Avoid/Use Alternative

crizotinib + amiodarone

use alternative or monitor ECG, electrolytes, HR, BP: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• amisulpride
Xalkori (crizotinib)

+

amisulpride

1 interaction

Avoid/Use Alternative

crizotinib + amisulpride

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Xalkori (crizotinib)

+

amitriptyline

1 interaction

Avoid/Use Alternative

crizotinib + amitriptyline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anagrelide
Xalkori (crizotinib)

+

anagrelide

1 interaction

Avoid/Use Alternative

crizotinib + anagrelide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Xalkori (crizotinib)

+

apalutamide

1 interaction

Avoid/Use Alternative

crizotinib + apalutamide

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• apomorphine
Xalkori (crizotinib)

+

apomorphine

1 interaction

Avoid/Use Alternative

crizotinib + apomorphine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apraclonidine ophthalmic
Xalkori (crizotinib)

+

apraclonidine ophthalmic

1 interaction

Avoid/Use Alternative

crizotinib + apraclonidine ophthalmic

use alternative or monitor BP, HR if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of bradycardia (additive effects)

• aprepitant
Xalkori (crizotinib)

+

aprepitant

1 interaction

Avoid/Use Alternative

crizotinib + aprepitant

avoid combo w/ oral aprepitant; IV aprepitant use OK: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• arformoterol inhaled
Xalkori (crizotinib)

+

arformoterol inhaled

1 interaction

Avoid/Use Alternative

crizotinib + arformoterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• arsenic trioxide
Xalkori (crizotinib)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

crizotinib + arsenic trioxide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• artemether/lumefantrine
Xalkori (crizotinib)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

crizotinib + artemether/ lumefantrine

use alternative or monitor ECG, electrolytes: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• articaine
Xalkori (crizotinib)

+

articaine

1 interaction

Avoid/Use Alternative

crizotinib + articaine

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• asenapine
Xalkori (crizotinib)

+

asenapine

1 interaction

Avoid/Use Alternative

crizotinib + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atazanavir
Xalkori (crizotinib)

+

atazanavir

1 interaction

Avoid/Use Alternative

crizotinib + atazanavir

use alternative or monitor ECG, HR, BP, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• atenolol
Xalkori (crizotinib)

+

atenolol

1 interaction

Avoid/Use Alternative

crizotinib + atenolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• avapritinib
Xalkori (crizotinib)

+

avapritinib

1 interaction

Avoid/Use Alternative

crizotinib + avapritinib

GIST: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 100 mg qd; ADVANCED SYSTEMIC MASTOCYTOSIS: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 50 mg qd; INDOLENT SYSTEMIC MASTOCYTOSIS: avoid combo: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• azithromycin
Xalkori (crizotinib)

+

azithromycin

1 interaction

Avoid/Use Alternative

crizotinib + azithromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Xalkori (crizotinib)

+

bedaquiline

1 interaction

Avoid/Use Alternative

crizotinib + bedaquiline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• berotralstat
Xalkori (crizotinib)

+

berotralstat

1 interaction

Avoid/Use Alternative

crizotinib + berotralstat

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• betaxolol
Xalkori (crizotinib)

+

betaxolol

1 interaction

Avoid/Use Alternative

crizotinib + betaxolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• betaxolol ophthalmic
Xalkori (crizotinib)

+

betaxolol ophthalmic

1 interaction

Avoid/Use Alternative

crizotinib + betaxolol ophthalmic

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• bisoprolol
Xalkori (crizotinib)

+

bisoprolol

1 interaction

Avoid/Use Alternative

crizotinib + bisoprolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• bosentan
Xalkori (crizotinib)

+

bosentan

1 interaction

Avoid/Use Alternative

crizotinib + bosentan

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. bosentan levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• bosutinib
Xalkori (crizotinib)

+

bosutinib

1 interaction

Avoid/Use Alternative

crizotinib + bosutinib

avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• brigatinib
Xalkori (crizotinib)

+

brigatinib

1 interaction

Avoid/Use Alternative

crizotinib + brigatinib

use alternative or monitor BP, HR; decr. brigatinib dose by approx. 40% as follows: if taking 180 mg, decr. to 120 mg, if taking 120 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• bupivacaine
Xalkori (crizotinib)

+

bupivacaine

1 interaction

Avoid/Use Alternative

crizotinib + bupivacaine

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• bupivacaine liposomal
Xalkori (crizotinib)

+

bupivacaine liposomal

1 interaction

Avoid/Use Alternative

crizotinib + bupivacaine liposomal

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• buprenorphine
Xalkori (crizotinib)

+

buprenorphine

1 interaction

Avoid/Use Alternative

crizotinib + buprenorphine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• buspirone
Xalkori (crizotinib)

+

buspirone

1 interaction

Avoid/Use Alternative

crizotinib + buspirone

consider alternative or restart buspirone dose at 2.5 mg bid: combo may incr. buspirone levels, risk of adverse effects (hepatic metab. inhibited)

• butalbital
Xalkori (crizotinib)

+

butalbital

1 interaction

Avoid/Use Alternative

crizotinib + butalbital

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• cabozantinib
Xalkori (crizotinib)

+

cabozantinib

1 interaction

Avoid/Use Alternative

crizotinib + cabozantinib

use alternative or monitor ECG, electrolytes, BP, bleeding s/sx: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• carbamazepine
Xalkori (crizotinib)

+

carbamazepine

1 interaction

Avoid/Use Alternative

crizotinib + carbamazepine

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. carbamazepine levels, risk of bradycardia, other adverse effects (hepatic metab. induced; hepatic metab. inhibited, additive effects)

• carteolol ophthalmic
Xalkori (crizotinib)

+

carteolol ophthalmic

1 interaction

Avoid/Use Alternative

crizotinib + carteolol ophthalmic

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• carvedilol
Xalkori (crizotinib)

+

carvedilol

1 interaction

Avoid/Use Alternative

crizotinib + carvedilol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• cenobamate
Xalkori (crizotinib)

+

cenobamate

1 interaction

Avoid/Use Alternative

crizotinib + cenobamate

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• chloramphenicol
Xalkori (crizotinib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

crizotinib + chloramphenicol

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• chloroprocaine
Xalkori (crizotinib)

+

chloroprocaine

1 interaction

Avoid/Use Alternative

crizotinib + chloroprocaine

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• chloroquine
Xalkori (crizotinib)

+

chloroquine

1 interaction

Avoid/Use Alternative

crizotinib + chloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorpromazine
Xalkori (crizotinib)

+

chlorpromazine

1 interaction

Avoid/Use Alternative

crizotinib + chlorpromazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ciprofloxacin
Xalkori (crizotinib)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

crizotinib + ciprofloxacin

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• citalopram
Xalkori (crizotinib)

+

citalopram

1 interaction

Avoid/Use Alternative

crizotinib + citalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cladribine oral
Xalkori (crizotinib)

+

cladribine oral

1 interaction

Avoid/Use Alternative

crizotinib + cladribine oral

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clarithromycin
Xalkori (crizotinib)

+

clarithromycin

1 interaction

Avoid/Use Alternative

crizotinib + clarithromycin

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• clofazimine
Xalkori (crizotinib)

+

clofazimine

1 interaction

Avoid/Use Alternative

crizotinib + clofazimine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• clomipramine
Xalkori (crizotinib)

+

clomipramine

1 interaction

Avoid/Use Alternative

crizotinib + clomipramine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clozapine
Xalkori (crizotinib)

+

clozapine

1 interaction

Avoid/Use Alternative

crizotinib + clozapine

use alternative or monitor ECG, BP, HR, CBC, electrolytes; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, severe bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• cobicistat
Xalkori (crizotinib)

+

cobicistat

1 interaction

Avoid/Use Alternative

crizotinib + cobicistat

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• cobimetinib
Xalkori (crizotinib)

+

cobimetinib

1 interaction

Avoid/Use Alternative

crizotinib + cobimetinib

avoid combo or decr. cobimetinib dose to 20 mg/day and limit tx w/ crizotinib to 14 days: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metab. inhibited)

• codeine
Xalkori (crizotinib)

+

codeine

1 interaction

Avoid/Use Alternative

crizotinib + codeine

use alternative or monitor resp. rate; consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine)

• colchicine
Xalkori (crizotinib)

+

colchicine

1 interaction

Avoid/Use Alternative

crizotinib + colchicine

CV RISK REDUCTION: avoid combo if renal or hepatic impairment; otherwise, monitor CBC, CK, myopathy s/sx; GOUT or FMF: use alternative or monitor CBC; decr. colchicine dose based on indication during and x14 days after crizotinib use as follows: GOUT PROPHYLAXIS: give colchicine 0.3-0.6 mg/day divided qd-bid; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 1.2 mg x1 only; FMF: decr. max colchicine dose to 1.2 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myelosuppression, myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited, additive effects)

• conivaptan
Xalkori (crizotinib)

+

conivaptan

1 interaction

Avoid/Use Alternative

crizotinib + conivaptan

use alternative or monitor ECG, electrolytes, CBC during and x7 days after conivaptan tx: combo may incr. levels of both drugs, risk of overly rapid serum sodium correction, neurologic sequelae, QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dabrafenib
Xalkori (crizotinib)

+

dabrafenib

1 interaction

Avoid/Use Alternative

crizotinib + dabrafenib

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• dasatinib
Xalkori (crizotinib)

+

dasatinib

1 interaction

Avoid/Use Alternative

crizotinib + dasatinib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• defactinib
Xalkori (crizotinib)

+

defactinib

1 interaction

Avoid/Use Alternative

crizotinib + defactinib

avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metab. inhibited)

• deferiprone
Xalkori (crizotinib)

+

deferiprone

1 interaction

Avoid/Use Alternative

crizotinib + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• degarelix
Xalkori (crizotinib)

+

degarelix

1 interaction

Avoid/Use Alternative

crizotinib + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Xalkori (crizotinib)

+

desflurane

1 interaction

Avoid/Use Alternative

crizotinib + desflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Xalkori (crizotinib)

+

desipramine

1 interaction

Avoid/Use Alternative

crizotinib + desipramine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• deutetrabenazine
Xalkori (crizotinib)

+

deutetrabenazine

1 interaction

Avoid/Use Alternative

crizotinib + deutetrabenazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine
Xalkori (crizotinib)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

crizotinib + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• dexmedetomidine injection
Xalkori (crizotinib)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

crizotinib + dexmedetomidine injection

use alternative or monitor HR, BP, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• dexrazoxane
Xalkori (crizotinib)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

crizotinib + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• digoxin
Xalkori (crizotinib)

+

digoxin

1 interaction

Avoid/Use Alternative

crizotinib + digoxin

use alternative or monitor HR: combo may incr. risk of bradycardia (additive effects)

• dihydrocodeine
Xalkori (crizotinib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

crizotinib + dihydrocodeine

use alternative or monitor resp. rate, consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite dihydromorphine)

• dihydroergotamine
Xalkori (crizotinib)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

crizotinib + dihydroergotamine

use alternative: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• diltiazem
Xalkori (crizotinib)

+

diltiazem

1 interaction

Avoid/Use Alternative

crizotinib + diltiazem

use alternative or monitor HR, BP, ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• disopyramide
Xalkori (crizotinib)

+

disopyramide

1 interaction

Avoid/Use Alternative

crizotinib + disopyramide

use alternative or monitor disopyramide levels, ECG, electrolytes: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dofetilide
Xalkori (crizotinib)

+

dofetilide

1 interaction

Avoid/Use Alternative

crizotinib + dofetilide

use alternative or monitor ECG, electrolytes: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, renal transport possibly inhibited, additive effects)

• donepezil
Xalkori (crizotinib)

+

donepezil

1 interaction

Avoid/Use Alternative

crizotinib + donepezil

use alternative or monitor ECG, HR, BP, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• dordaviprone
Xalkori (crizotinib)

+

dordaviprone

1 interaction

Avoid/Use Alternative

crizotinib + dordaviprone

use alternative or monitor ECG, electrolytes; separate admin.; for adult and pediatric pts weighing at least 52.5 kg, decr. dordaviprone dose to 500 mg once weekly; dose recommendation not established in pediatric pts weighing less than 52.5 kg: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• doxorubicin
Xalkori (crizotinib)

+

doxorubicin

1 interaction

Avoid/Use Alternative

crizotinib + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metab. inhibited)

• droperidol
Xalkori (crizotinib)

+

droperidol

1 interaction

Avoid/Use Alternative

crizotinib + droperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dulaglutide
Xalkori (crizotinib)

+

dulaglutide

1 interaction

Avoid/Use Alternative

crizotinib + dulaglutide

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• efavirenz
Xalkori (crizotinib)

+

efavirenz

1 interaction

Avoid/Use Alternative

crizotinib + efavirenz

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• elacestrant
Xalkori (crizotinib)

+

elacestrant

1 interaction

Avoid/Use Alternative

crizotinib + elacestrant

avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metab. inhibited)

• encorafenib
Xalkori (crizotinib)

+

encorafenib

1 interaction

Avoid/Use Alternative

crizotinib + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• ensartinib
Xalkori (crizotinib)

+

ensartinib

1 interaction

Avoid/Use Alternative

crizotinib + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metab. possibly inhibited, additive effects)

• entrectinib
Xalkori (crizotinib)

+

entrectinib

1 interaction

Avoid/Use Alternative

crizotinib + entrectinib

avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• enzalutamide
Xalkori (crizotinib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

crizotinib + enzalutamide

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• ephedra
Xalkori (crizotinib)

+

ephedra

1 interaction

Avoid/Use Alternative

crizotinib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Xalkori (crizotinib)

+

epirubicin

1 interaction

Avoid/Use Alternative

crizotinib + epirubicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ergotamine
Xalkori (crizotinib)

+

ergotamine

1 interaction

Avoid/Use Alternative

crizotinib + ergotamine

use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• eribulin
Xalkori (crizotinib)

+

eribulin

1 interaction

Avoid/Use Alternative

crizotinib + eribulin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Xalkori (crizotinib)

+

erythromycin

1 interaction

Avoid/Use Alternative

crizotinib + erythromycin

use alternative or monitor ECG, electrolytes, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• escitalopram
Xalkori (crizotinib)

+

escitalopram

1 interaction

Avoid/Use Alternative

crizotinib + escitalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• esmolol
Xalkori (crizotinib)

+

esmolol

1 interaction

Avoid/Use Alternative

crizotinib + esmolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• etrasimod
Xalkori (crizotinib)

+

etrasimod

1 interaction

Avoid/Use Alternative

crizotinib + etrasimod

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, use alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• etravirine
Xalkori (crizotinib)

+

etravirine

1 interaction

Avoid/Use Alternative

crizotinib + etravirine

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• fentanyl
Xalkori (crizotinib)

+

fentanyl

1 interaction

Avoid/Use Alternative

crizotinib + fentanyl

use alternative or monitor resp. rate, HR, BP; consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• fexinidazole
Xalkori (crizotinib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

crizotinib + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after crizotinib D/C; use alternative or monitor CBC, ECG, electrolytes during and x7 days after fexinidazole tx: combo may incr. or decr. crizotinib levels, incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects or decr. efficacy; may decr. fexinidazole active metabolite levels, efficacy (renal transport possibly inhibited, hepatic metab. induced; additive effects, bradycardia may incr. risk of QT prolongation; hepatic metab. inhibited, decr. conversion to active metabolites)

• fingolimod
Xalkori (crizotinib)

+

fingolimod

1 interaction

Avoid/Use Alternative

crizotinib + fingolimod

use alternative or monitor electrolytes, HR, BP, ECG overnight, esp. during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• flecainide
Xalkori (crizotinib)

+

flecainide

1 interaction

Avoid/Use Alternative

crizotinib + flecainide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Xalkori (crizotinib)

+

fluconazole

1 interaction

Avoid/Use Alternative

crizotinib + fluconazole

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• fluorouracil
Xalkori (crizotinib)

+

fluorouracil

1 interaction

Avoid/Use Alternative

crizotinib + fluorouracil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Xalkori (crizotinib)

+

fluoxetine

1 interaction

Avoid/Use Alternative

crizotinib + fluoxetine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• formoterol inhaled
Xalkori (crizotinib)

+

formoterol inhaled

1 interaction

Avoid/Use Alternative

crizotinib + formoterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• fosaprepitant
Xalkori (crizotinib)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

crizotinib + fosaprepitant

avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metab. inhibited)

• foscarnet
Xalkori (crizotinib)

+

foscarnet

1 interaction

Avoid/Use Alternative

crizotinib + foscarnet

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia, myelosuppression (additive effects)

• fosphenytoin
Xalkori (crizotinib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

crizotinib + fosphenytoin

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• fostemsavir
Xalkori (crizotinib)

+

fostemsavir

1 interaction

Avoid/Use Alternative

crizotinib + fostemsavir

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• galantamine
Xalkori (crizotinib)

+

galantamine

1 interaction

Avoid/Use Alternative

crizotinib + galantamine

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• ganciclovir
Xalkori (crizotinib)

+

ganciclovir

1 interaction

Avoid/Use Alternative

crizotinib + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gemtuzumab ozogamicin
Xalkori (crizotinib)

+

gemtuzumab ozogamicin

1 interaction

Avoid/Use Alternative

crizotinib + gemtuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepirone
Xalkori (crizotinib)

+

gepirone

1 interaction

Avoid/Use Alternative

crizotinib + gepirone

use alternative or monitor ECG, electrolytes; decr. gepirone dose 50%: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• gepotidacin
Xalkori (crizotinib)

+

gepotidacin

1 interaction

Avoid/Use Alternative

crizotinib + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Xalkori (crizotinib)

+

gilteritinib

1 interaction

Avoid/Use Alternative

crizotinib + gilteritinib

use alternative or monitor ECG, electrolytes: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• givinostat
Xalkori (crizotinib)

+

givinostat

1 interaction

Avoid/Use Alternative

crizotinib + givinostat

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (renal transport possibly inhibited, additive effects)

• glasdegib
Xalkori (crizotinib)

+

glasdegib

1 interaction

Avoid/Use Alternative

crizotinib + glasdegib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• goserelin
Xalkori (crizotinib)

+

goserelin

1 interaction

Avoid/Use Alternative

crizotinib + goserelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• granisetron
Xalkori (crizotinib)

+

granisetron

1 interaction

Avoid/Use Alternative

crizotinib + granisetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• grapefruit
Xalkori (crizotinib)

+

grapefruit

1 interaction

Avoid/Use Alternative

crizotinib + grapefruit

avoid grapefruit juice: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (GI metab. inhibited, additive effects)

• guanfacine
Xalkori (crizotinib)

+

guanfacine

1 interaction

Avoid/Use Alternative

crizotinib + guanfacine

use alternative or monitor HR, BP; decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• haloperidol
Xalkori (crizotinib)

+

haloperidol

1 interaction

Avoid/Use Alternative

crizotinib + haloperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Xalkori (crizotinib)

+

histrelin

1 interaction

Avoid/Use Alternative

crizotinib + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Xalkori (crizotinib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

crizotinib + hydrocodone

use alternative or monitor resp. rate, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• hydroxychloroquine
Xalkori (crizotinib)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

crizotinib + hydroxychloroquine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• hydroxyzine
Xalkori (crizotinib)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

crizotinib + hydroxyzine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Xalkori (crizotinib)

+

ibutilide

1 interaction

Avoid/Use Alternative

crizotinib + ibutilide

use alternative or monitor ECG, electrolytes, HR, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• idelalisib
Xalkori (crizotinib)

+

idelalisib

1 interaction

Avoid/Use Alternative

crizotinib + idelalisib

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• iloperidone
Xalkori (crizotinib)

+

iloperidone

1 interaction

Avoid/Use Alternative

crizotinib + iloperidone

use alternative or monitor ECG, electrolytes: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• inotuzumab ozogamicin
Xalkori (crizotinib)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

crizotinib + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoflurane
Xalkori (crizotinib)

+

isoflurane

1 interaction

Avoid/Use Alternative

crizotinib + isoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• itraconazole
Xalkori (crizotinib)

+

itraconazole

1 interaction

Avoid/Use Alternative

crizotinib + itraconazole

use alternative or monitor ECG, electrolytes, CBC, consider decr. itraconazole dose, adjust crizotinib dose during and x2wk after itraconazole; Adults w/ NSCLC, IMT: decr. crizotinib to 250 mg qd; Peds w/ IMT, Adult/Peds w/ ALCL: decr. crizotinib: BSA 0.38-0.46 m^2, 70 mg bid; BSA 0.47-0.51 m^2, 80 mg bid; BSA 0.52-0.61 m^2, 90 mg bid; BSA 0.62-0.8 m^2, 120 mg bid; BSA 0.81-0.97 m^2, 150 mg bid; BSA 0.98-1.16 m^2, 170 mg bid; BSA 1.17-1.69 m^2, 200 mg bid; BSA 1.7 m^2 or greater, 250 mg bid: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ivabradine
Xalkori (crizotinib)

+

ivabradine

1 interaction

Avoid/Use Alternative

crizotinib + ivabradine

avoid combo: combo may incr. ivabradine levels, risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ivacaftor
Xalkori (crizotinib)

+

ivacaftor

1 interaction

Avoid/Use Alternative

crizotinib + ivacaftor

pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg qd; 6 mo-5 yo and 7-13.9 kg: give 50 mg qd; 6 mo-5 yo and >14 kg: give 75 mg qd; 6 yo and older: give 150 mg qd: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• ivosidenib
Xalkori (crizotinib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

crizotinib + ivosidenib

avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• ixabepilone
Xalkori (crizotinib)

+

ixabepilone

1 interaction

Avoid/Use Alternative

crizotinib + ixabepilone

consider alternatives or monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• ketoconazole
Xalkori (crizotinib)

+

ketoconazole

1 interaction

Avoid/Use Alternative

crizotinib + ketoconazole

use alternative or monitor ECG, electrolytes, CBC, adjust crizotinib during and up to 1wk after ketoconazole; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• labetalol
Xalkori (crizotinib)

+

labetalol

1 interaction

Avoid/Use Alternative

crizotinib + labetalol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• lacosamide
Xalkori (crizotinib)

+

lacosamide

1 interaction

Avoid/Use Alternative

crizotinib + lacosamide

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• lamotrigine
Xalkori (crizotinib)

+

lamotrigine

1 interaction

Avoid/Use Alternative

crizotinib + lamotrigine

use alternative or monitor HR, BP, ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects (renal transport possibly inhibited, additive effects)

• landiolol
Xalkori (crizotinib)

+

landiolol

1 interaction

Avoid/Use Alternative

crizotinib + landiolol

avoid combo: combo may incr. risk of bradycardia (additive effects)

• lapatinib
Xalkori (crizotinib)

+

lapatinib

1 interaction

Avoid/Use Alternative

crizotinib + lapatinib

use alternative or monitor ECG, electrolytes; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lasmiditan
Xalkori (crizotinib)

+

lasmiditan

1 interaction

Avoid/Use Alternative

crizotinib + lasmiditan

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• lefamulin
Xalkori (crizotinib)

+

lefamulin

1 interaction

Avoid/Use Alternative

crizotinib + lefamulin

use alternative or monitor ECG, electrolytes, CBC: combo w/ oral lefamulin may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; combo w/ IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. inhibited, additive effects)

• lemborexant
Xalkori (crizotinib)

+

lemborexant

1 interaction

Avoid/Use Alternative

crizotinib + lemborexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lenvatinib
Xalkori (crizotinib)

+

lenvatinib

1 interaction

Avoid/Use Alternative

crizotinib + lenvatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• leuprolide
Xalkori (crizotinib)

+

leuprolide

1 interaction

Avoid/Use Alternative

crizotinib + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levalbuterol inhaled
Xalkori (crizotinib)

+

levalbuterol inhaled

1 interaction

Avoid/Use Alternative

crizotinib + levalbuterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• levobunolol ophthalmic
Xalkori (crizotinib)

+

levobunolol ophthalmic

1 interaction

Avoid/Use Alternative

crizotinib + levobunolol ophthalmic

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• levofloxacin
Xalkori (crizotinib)

+

levofloxacin

1 interaction

Avoid/Use Alternative

crizotinib + levofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lidocaine
Xalkori (crizotinib)

+

lidocaine

1 interaction

Avoid/Use Alternative

crizotinib + lidocaine

use alternative or monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher w/ continuous infusion or higher doses for local anesthesia (hepatic metab. inhibited, additive effects)

• lofexidine
Xalkori (crizotinib)

+

lofexidine

1 interaction

Avoid/Use Alternative

crizotinib + lofexidine

use alternative or monitor ECG, electrolytes, BP, HR: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• lonafarnib
Xalkori (crizotinib)

+

lonafarnib

1 interaction

Avoid/Use Alternative

crizotinib + lonafarnib

use alternative or monitor HR, ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• loperamide
Xalkori (crizotinib)

+

loperamide

1 interaction

Avoid/Use Alternative

crizotinib + loperamide

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Xalkori (crizotinib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

crizotinib + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. crizotinib levels, incr. risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects or decr. efficacy (hepatic metab. altered, additive effects)

• lorlatinib
Xalkori (crizotinib)

+

lorlatinib

1 interaction

Avoid/Use Alternative

crizotinib + lorlatinib

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. risk of bradycardia (hepatic metab. induced; additive effects)

• lovastatin
Xalkori (crizotinib)

+

lovastatin

1 interaction

Avoid/Use Alternative

crizotinib + lovastatin

use alternative or monitor CK, myopathy sx; adjust lovastatin max dose to 20 mg/day: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• lumacaftor/ivacaftor
Xalkori (crizotinib)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

crizotinib + lumacaftor/ ivacaftor

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. ivacaftor levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• lumateperone
Xalkori (crizotinib)

+

lumateperone

1 interaction

Avoid/Use Alternative

crizotinib + lumateperone

use alternative or monitor ECG, electrolytes; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lurasidone
Xalkori (crizotinib)

+

lurasidone

1 interaction

Avoid/Use Alternative

crizotinib + lurasidone

use alternative or monitor ECG, electrolytes; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lurbinectedin
Xalkori (crizotinib)

+

lurbinectedin

1 interaction

Avoid/Use Alternative

crizotinib + lurbinectedin

use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• macimorelin
Xalkori (crizotinib)

+

macimorelin

1 interaction

Avoid/Use Alternative

crizotinib + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• macitentan
Xalkori (crizotinib)

+

macitentan

1 interaction

Avoid/Use Alternative

crizotinib + macitentan

if also combined w/ strong-mod CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. macitentan levels, risk of adverse effects (hepatic metab. inhibited)

• mavacamten
Xalkori (crizotinib)

+

mavacamten

1 interaction

Avoid/Use Alternative

crizotinib + mavacamten

avoid combo: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• mavorixafor
Xalkori (crizotinib)

+

mavorixafor

1 interaction

Avoid/Use Alternative

crizotinib + mavorixafor

use alternative or monitor ECG, electrolytes: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• mefloquine
Xalkori (crizotinib)

+

mefloquine

1 interaction

Avoid/Use Alternative

crizotinib + mefloquine

use alternative or monitor ECG, HR, BP, electrolytes: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• meperidine
Xalkori (crizotinib)

+

meperidine

1 interaction

Avoid/Use Alternative

crizotinib + meperidine

use alternative or monitor resp. rate, ECG, electrolytes; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• mepivacaine
Xalkori (crizotinib)

+

mepivacaine

1 interaction

Avoid/Use Alternative

crizotinib + mepivacaine

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• methadone
Xalkori (crizotinib)

+

methadone

1 interaction

Avoid/Use Alternative

crizotinib + methadone

use alternative or monitor resp. rate, ECG, electrolytes; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• methylergonovine
Xalkori (crizotinib)

+

methylergonovine

1 interaction

Avoid/Use Alternative

crizotinib + methylergonovine

avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• metoprolol
Xalkori (crizotinib)

+

metoprolol

1 interaction

Avoid/Use Alternative

crizotinib + metoprolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• metronidazole
Xalkori (crizotinib)

+

metronidazole

1 interaction

Avoid/Use Alternative

crizotinib + metronidazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midazolam
Xalkori (crizotinib)

+

midazolam

1 interaction

Avoid/Use Alternative

crizotinib + midazolam

avoid combo if midazolam nasal use; otherwise, monitor resp. rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• midostaurin
Xalkori (crizotinib)

+

midostaurin

1 interaction

Avoid/Use Alternative

crizotinib + midostaurin

use alternative or monitor ECG, electrolytes, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• mifepristone
Xalkori (crizotinib)

+

mifepristone

1 interaction

Avoid/Use Alternative

crizotinib + mifepristone

use alternative or monitor ECG, electrolytes, CBC, adjust crizotinib dose during and x14 days after daily mifepristone; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib: BSA 0.38-0.46 m^2, 70 mg bid; BSA 0.47-0.51 m^2, 80 mg bid; BSA 0.52-0.61 m^2, 90 mg bid; BSA 0.62-0.8 m^2, 120 mg bid; BSA 0.81-0.97 m^2, 150 mg bid; BSA 0.98-1.16 m^2, 170 mg bid; BSA 1.17-1.69 m^2, 200 mg bid; BSA 1.7 m^2 or greater, 250 mg bid: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypokalemia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• mirtazapine
Xalkori (crizotinib)

+

mirtazapine

1 interaction

Avoid/Use Alternative

crizotinib + mirtazapine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mitapivat
Xalkori (crizotinib)

+

mitapivat

1 interaction

Avoid/Use Alternative

crizotinib + mitapivat

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• mitotane
Xalkori (crizotinib)

+

mitotane

1 interaction

Avoid/Use Alternative

crizotinib + mitotane

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• mobocertinib
Xalkori (crizotinib)

+

mobocertinib

1 interaction

Avoid/Use Alternative

crizotinib + mobocertinib

use alternative or monitor ECG, electrolytes; decr. mobocertinib dose as follows: if taking 160 mg, decr. dose to 80 mg; if taking 120 mg, decr. dose to 40 mg, if taking 80 mg, decr. dose to 40 mg: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• modafinil
Xalkori (crizotinib)

+

modafinil

1 interaction

Avoid/Use Alternative

crizotinib + modafinil

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• moxifloxacin
Xalkori (crizotinib)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

crizotinib + moxifloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nadolol
Xalkori (crizotinib)

+

nadolol

1 interaction

Avoid/Use Alternative

crizotinib + nadolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• nafcillin
Xalkori (crizotinib)

+

nafcillin

1 interaction

Avoid/Use Alternative

crizotinib + nafcillin

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• naloxegol
Xalkori (crizotinib)

+

naloxegol

1 interaction

Avoid/Use Alternative

crizotinib + naloxegol

use alternative or decr. naloxegol dose to 12.5 mg/day: combo may incr. naloxegol levels, risk of adverse effects (hepatic metab. inhibited)

• nebivolol
Xalkori (crizotinib)

+

nebivolol

1 interaction

Avoid/Use Alternative

crizotinib + nebivolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• nefazodone
Xalkori (crizotinib)

+

nefazodone

1 interaction

Avoid/Use Alternative

crizotinib + nefazodone

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• nelfinavir
Xalkori (crizotinib)

+

nelfinavir

1 interaction

Avoid/Use Alternative

crizotinib + nelfinavir

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• neostigmine
Xalkori (crizotinib)

+

neostigmine

1 interaction

Avoid/Use Alternative

crizotinib + neostigmine

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• neratinib
Xalkori (crizotinib)

+

neratinib

1 interaction

Avoid/Use Alternative

crizotinib + neratinib

avoid combo if also combined w/ P-gp inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (hepatic metab. inhibited)

• nilotinib
Xalkori (crizotinib)

+

nilotinib

1 interaction

Avoid/Use Alternative

crizotinib + nilotinib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypokalemia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• nirogacestat
Xalkori (crizotinib)

+

nirogacestat

1 interaction

Avoid/Use Alternative

crizotinib + nirogacestat

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hypophosphatemia, other adverse effects (hepatic metab. inhibited)

• nisoldipine
Xalkori (crizotinib)

+

nisoldipine

1 interaction

Avoid/Use Alternative

crizotinib + nisoldipine

consider alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• octreotide
Xalkori (crizotinib)

+

octreotide

1 interaction

Avoid/Use Alternative

crizotinib + octreotide

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• ofloxacin
Xalkori (crizotinib)

+

ofloxacin

1 interaction

Avoid/Use Alternative

crizotinib + ofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olaparib
Xalkori (crizotinib)

+

olaparib

1 interaction

Avoid/Use Alternative

crizotinib + olaparib

use alternative or monitor CBC; decr. olaparib dose to 150 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• oliceridine
Xalkori (crizotinib)

+

oliceridine

1 interaction

Avoid/Use Alternative

crizotinib + oliceridine

use alternative or monitor resp. rate, ECG, electrolytes; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• olodaterol inhaled
Xalkori (crizotinib)

+

olodaterol inhaled

1 interaction

Avoid/Use Alternative

crizotinib + olodaterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• omaveloxolone
Xalkori (crizotinib)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

crizotinib + omaveloxolone

use alternative or decr. omaveloxolone dose to 100 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• ondansetron
Xalkori (crizotinib)

+

ondansetron

1 interaction

Avoid/Use Alternative

crizotinib + ondansetron

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (renal transport inhibited, additive effects)

• osilodrostat
Xalkori (crizotinib)

+

osilodrostat

1 interaction

Avoid/Use Alternative

crizotinib + osilodrostat

use alternative or monitor ECG, electrolytes: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, hypokalemia, other adverse effects (hepatic metab. inhibited; additive effects)

• osimertinib
Xalkori (crizotinib)

+

osimertinib

1 interaction

Avoid/Use Alternative

crizotinib + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Xalkori (crizotinib)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

crizotinib + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxycodone
Xalkori (crizotinib)

+

oxycodone

1 interaction

Avoid/Use Alternative

crizotinib + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ozanimod
Xalkori (crizotinib)

+

ozanimod

1 interaction

Avoid/Use Alternative

crizotinib + ozanimod

use alternative or monitor HR, BP, ECG, electrolytes, especially when starting or restarting ozanimod tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• pacritinib
Xalkori (crizotinib)

+

pacritinib

1 interaction

Avoid/Use Alternative

crizotinib + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• palifermin
Xalkori (crizotinib)

+

palifermin

1 interaction

Avoid/Use Alternative

crizotinib + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• paliperidone
Xalkori (crizotinib)

+

paliperidone

1 interaction

Avoid/Use Alternative

crizotinib + paliperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Xalkori (crizotinib)

+

palonosetron

1 interaction

Avoid/Use Alternative

crizotinib + palonosetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palovarotene
Xalkori (crizotinib)

+

palovarotene

1 interaction

Avoid/Use Alternative

crizotinib + palovarotene

use alternative or decr. palovarotene dose as follows: wt 10-19.9 kg maint. dose 1 mg daily, flare dose 5 mg daily wk 1-4, then 2.5 mg daily wk 5-12; wt 20-39.9 kg maint. dose 1.5 mg daily, flare dose 6 mg daily wk 1-4, then 3 mg daily wk 5-12; wt 40-59.9 kg maint. dose 2 mg daily, flare dose 7.5 mg daily wk 1-4, then 4 mg daily wk 5-12; wt 60 kg and greater or 14 yo and older maint. dose 2.5 mg daily, flare dose 10 mg daily wk 1-4, then 5 mg daily wk 5-12: combo may incr. palovarotene levels, risk of adverse effects (hepatic metab. inhibited)

• paltusotine
Xalkori (crizotinib)

+

paltusotine

1 interaction

Avoid/Use Alternative

crizotinib + paltusotine

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• panobinostat
Xalkori (crizotinib)

+

panobinostat

1 interaction

Avoid/Use Alternative

crizotinib + panobinostat

use alternative or monitor ECG, CBC, electrolytes: combo may incr. panobinostat levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• pasireotide
Xalkori (crizotinib)

+

pasireotide

1 interaction

Avoid/Use Alternative

crizotinib + pasireotide

use alternative or monitor ECG, HR, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• pazopanib
Xalkori (crizotinib)

+

pazopanib

1 interaction

Avoid/Use Alternative

crizotinib + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• pemigatinib
Xalkori (crizotinib)

+

pemigatinib

1 interaction

Avoid/Use Alternative

crizotinib + pemigatinib

use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• penicillamine
Xalkori (crizotinib)

+

penicillamine

1 interaction

Avoid/Use Alternative

crizotinib + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Xalkori (crizotinib)

+

pentamidine

1 interaction

Avoid/Use Alternative

crizotinib + pentamidine

use alternative or monitor ECG, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• pentobarbital
Xalkori (crizotinib)

+

pentobarbital

1 interaction

Avoid/Use Alternative

crizotinib + pentobarbital

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• pexidartinib
Xalkori (crizotinib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

crizotinib + pexidartinib

avoid combo: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• phenobarbital
Xalkori (crizotinib)

+

phenobarbital

1 interaction

Avoid/Use Alternative

crizotinib + phenobarbital

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• phenytoin
Xalkori (crizotinib)

+

phenytoin

1 interaction

Avoid/Use Alternative

crizotinib + phenytoin

avoid combo: combo may decr. crizotinib levels, efficacy; may incr. risk of bradycardia (hepatic metab. induced; additive effects)

• pimavanserin
Xalkori (crizotinib)

+

pimavanserin

1 interaction

Avoid/Use Alternative

crizotinib + pimavanserin

avoid combo: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• pindolol
Xalkori (crizotinib)

+

pindolol

1 interaction

Avoid/Use Alternative

crizotinib + pindolol

use alternative or monitor HR, BP: combo may incr. pindolol levels, risk of hypotension, bradycardia, other adverse effects (renal transport possibly inhibited, additive effects)

• pitolisant
Xalkori (crizotinib)

+

pitolisant

1 interaction

Avoid/Use Alternative

crizotinib + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Xalkori (crizotinib)

+

ponesimod

1 interaction

Avoid/Use Alternative

crizotinib + ponesimod

use alternative or monitor HR, BP, ECG, electrolytes, especially when starting or restarting ponesimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• porfimer
Xalkori (crizotinib)

+

porfimer

1 interaction

Avoid/Use Alternative

crizotinib + porfimer

avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)

• pralsetinib
Xalkori (crizotinib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

crizotinib + pralsetinib

use alternative or monitor ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• praziquantel
Xalkori (crizotinib)

+

praziquantel

1 interaction

Avoid/Use Alternative

crizotinib + praziquantel

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• primaquine
Xalkori (crizotinib)

+

primaquine

1 interaction

Avoid/Use Alternative

crizotinib + primaquine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• primidone
Xalkori (crizotinib)

+

primidone

1 interaction

Avoid/Use Alternative

crizotinib + primidone

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• procainamide
Xalkori (crizotinib)

+

procainamide

1 interaction

Avoid/Use Alternative

crizotinib + procainamide

use alternative or monitor procainamide levels, ECG, electrolytes: combo may incr. procainamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport possibly inhibited, additive effects)

• promethazine
Xalkori (crizotinib)

+

promethazine

1 interaction

Avoid/Use Alternative

crizotinib + promethazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Xalkori (crizotinib)

+

propafenone

1 interaction

Avoid/Use Alternative

crizotinib + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, use alternative or monitor ECG, electrolytes, HR, BP: combo may incr. propafenone levels, risk of QT prolongation, bradycardia, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited, additive effects)

• propofol
Xalkori (crizotinib)

+

propofol

1 interaction

Avoid/Use Alternative

crizotinib + propofol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• propranolol
Xalkori (crizotinib)

+

propranolol

1 interaction

Avoid/Use Alternative

crizotinib + propranolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• pyridostigmine
Xalkori (crizotinib)

+

pyridostigmine

1 interaction

Avoid/Use Alternative

crizotinib + pyridostigmine

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• quetiapine
Xalkori (crizotinib)

+

quetiapine

1 interaction

Avoid/Use Alternative

crizotinib + quetiapine

use alternative or monitor ECG, electrolytes; consider decr. quetiapine dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• quinidine (antiarrhythmic)
Xalkori (crizotinib)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

crizotinib + quinidine (antiarrhythmic)

use alternative or monitor quinidine levels, ECG, electrolytes, HR, BP, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, renal transport inhibited, additive effects)

• quinidine (CYP2D6 inhibitor)
Xalkori (crizotinib)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

crizotinib + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG, electrolytes: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• quinine
Xalkori (crizotinib)

+

quinine

1 interaction

Avoid/Use Alternative

crizotinib + quinine

use alternative or monitor ECG, electrolytes: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• quizartinib
Xalkori (crizotinib)

+

quizartinib

1 interaction

Avoid/Use Alternative

crizotinib + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• radium Ra 223 dichloride
Xalkori (crizotinib)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

crizotinib + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ranolazine
Xalkori (crizotinib)

+

ranolazine

1 interaction

Avoid/Use Alternative

crizotinib + ranolazine

use alternative or monitor ECG, electrolytes, CBC; adjust ranolazine max dose to 1000 mg/day: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, renal transport inhibited, additive effects)

• relugolix
Xalkori (crizotinib)

+

relugolix

1 interaction

Avoid/Use Alternative

crizotinib + relugolix

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• remibrutinib
Xalkori (crizotinib)

+

remibrutinib

1 interaction

Avoid/Use Alternative

crizotinib + remibrutinib

avoid combo: combo may incr. remibrutinib levels, risk of adverse effects (hepatic metab. inhibited)

• remimazolam
Xalkori (crizotinib)

+

remimazolam

1 interaction

Avoid/Use Alternative

crizotinib + remimazolam

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• repotrectinib
Xalkori (crizotinib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

crizotinib + repotrectinib

avoid combo; D/C crizotinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• revumenib
Xalkori (crizotinib)

+

revumenib

1 interaction

Avoid/Use Alternative

crizotinib + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Xalkori (crizotinib)

+

ribociclib

1 interaction

Avoid/Use Alternative

crizotinib + ribociclib

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, renal transport inhibited, additive effects)

• rifabutin
Xalkori (crizotinib)

+

rifabutin

1 interaction

Avoid/Use Alternative

crizotinib + rifabutin

avoid combo: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• rifampin
Xalkori (crizotinib)

+

rifampin

1 interaction

Avoid/Use Alternative

crizotinib + rifampin

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• rifapentine
Xalkori (crizotinib)

+

rifapentine

1 interaction

Avoid/Use Alternative

crizotinib + rifapentine

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• rilpivirine
Xalkori (crizotinib)

+

rilpivirine

1 interaction

Avoid/Use Alternative

crizotinib + rilpivirine

use alternative or monitor ECG, electrolytes; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rilzabrutinib
Xalkori (crizotinib)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

crizotinib + rilzabrutinib

avoid combo if crizotinib use greater than 7 days; use alternative or hold rilzabrutinib if crizotinib use less than 7 days: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ritonavir
Xalkori (crizotinib)

+

ritonavir

1 interaction

Avoid/Use Alternative

crizotinib + ritonavir

use alternative or monitor ECG, HR, BP, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• rivaroxaban
Xalkori (crizotinib)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

crizotinib + rivaroxaban

use alternative if CrCl <80 and combined w/ P-gp inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• rivastigmine
Xalkori (crizotinib)

+

rivastigmine

1 interaction

Avoid/Use Alternative

crizotinib + rivastigmine

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• romidepsin
Xalkori (crizotinib)

+

romidepsin

1 interaction

Avoid/Use Alternative

crizotinib + romidepsin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ropeginterferon alfa-2b
Xalkori (crizotinib)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

crizotinib + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rucaparib
Xalkori (crizotinib)

+

rucaparib

1 interaction

Avoid/Use Alternative

crizotinib + rucaparib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sacituzumab govitecan
Xalkori (crizotinib)

+

sacituzumab govitecan

1 interaction

Avoid/Use Alternative

crizotinib + sacituzumab govitecan

use alternative or monitor ECG, electrolytes, incl. potassium: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• salmeterol inhaled
Xalkori (crizotinib)

+

salmeterol inhaled

1 interaction

Avoid/Use Alternative

crizotinib + salmeterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• sebetralstat
Xalkori (crizotinib)

+

sebetralstat

1 interaction

Avoid/Use Alternative

crizotinib + sebetralstat

use alternative or monitor ECG, electrolytes; decr. sebetralstat dose to 300 mg, may give second 300 mg dose at least 3h after first dose if needed: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• selpercatinib
Xalkori (crizotinib)

+

selpercatinib

1 interaction

Avoid/Use Alternative

crizotinib + selpercatinib

use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 80 mg bid; if on selpercatinib 160 mg bid, decr. to 120 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• selumetinib
Xalkori (crizotinib)

+

selumetinib

1 interaction

Avoid/Use Alternative

crizotinib + selumetinib

use alternative or monitor LVEF, CK, myopathy sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• sertraline
Xalkori (crizotinib)

+

sertraline

1 interaction

Avoid/Use Alternative

crizotinib + sertraline

use alternative or monitor ECG, electrolytes: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• sevoflurane
Xalkori (crizotinib)

+

sevoflurane

1 interaction

Avoid/Use Alternative

crizotinib + sevoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• simvastatin
Xalkori (crizotinib)

+

simvastatin

1 interaction

Avoid/Use Alternative

crizotinib + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 10 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• siponimod
Xalkori (crizotinib)

+

siponimod

1 interaction

Avoid/Use Alternative

crizotinib + siponimod

use alternative or monitor BP, HR, ECG, electrolytes, especially when starting or restarting siponimod tx; if also combined w/ strong CYP2C9 inhibitor, avoid combo: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• solifenacin
Xalkori (crizotinib)

+

solifenacin

1 interaction

Avoid/Use Alternative

crizotinib + solifenacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sonidegib
Xalkori (crizotinib)

+

sonidegib

1 interaction

Avoid/Use Alternative

crizotinib + sonidegib

avoid combo or monitor closely: combo may incr. sonidegib levels, risk of adverse effects (hepatic metab. inhibited)

• sorafenib
Xalkori (crizotinib)

+

sorafenib

1 interaction

Avoid/Use Alternative

crizotinib + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Xalkori (crizotinib)

+

sotalol

1 interaction

Avoid/Use Alternative

crizotinib + sotalol

use alternative or monitor BP, HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

• sotorasib
Xalkori (crizotinib)

+

sotorasib

1 interaction

Avoid/Use Alternative

crizotinib + sotorasib

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• St. John's wort
Xalkori (crizotinib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

crizotinib + St. John's wort

avoid combo: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• sufentanil
Xalkori (crizotinib)

+

sufentanil

1 interaction

Avoid/Use Alternative

crizotinib + sufentanil

consider alternative or monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• sugammadex
Xalkori (crizotinib)

+

sugammadex

1 interaction

Avoid/Use Alternative

crizotinib + sugammadex

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• sunitinib
Xalkori (crizotinib)

+

sunitinib

1 interaction

Avoid/Use Alternative

crizotinib + sunitinib

use alternative or monitor ECG, electrolytes: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tacrolimus
Xalkori (crizotinib)

+

tacrolimus

1 interaction

Avoid/Use Alternative

crizotinib + tacrolimus

use alternative or monitor tacrolimus levels, ECG, electrolytes, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• taletrectinib
Xalkori (crizotinib)

+

taletrectinib

1 interaction

Avoid/Use Alternative

crizotinib + taletrectinib

avoid combo: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tazemetostat
Xalkori (crizotinib)

+

tazemetostat

1 interaction

Avoid/Use Alternative

crizotinib + tazemetostat

use alternative or monitor ECG, electrolytes, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• telavancin
Xalkori (crizotinib)

+

telavancin

1 interaction

Avoid/Use Alternative

crizotinib + telavancin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• terbutaline
Xalkori (crizotinib)

+

terbutaline

1 interaction

Avoid/Use Alternative

crizotinib + terbutaline

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• tetrabenazine
Xalkori (crizotinib)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

crizotinib + tetrabenazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• thalidomide
Xalkori (crizotinib)

+

thalidomide

1 interaction

Avoid/Use Alternative

crizotinib + thalidomide

use alternative or monitor HR, BP, CBC: combo may incr. risk of bradycardia, myelosuppression (additive effects)

• ticagrelor
Xalkori (crizotinib)

+

ticagrelor

1 interaction

Avoid/Use Alternative

crizotinib + ticagrelor

use alternative or monitor HR, BP: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• timolol
Xalkori (crizotinib)

+

timolol

1 interaction

Avoid/Use Alternative

crizotinib + timolol

use alternative or monitor HR, BP: combo may incr. risk of bradycardia (additive effects)

• timolol ophthalmic
Xalkori (crizotinib)

+

timolol ophthalmic

1 interaction

Avoid/Use Alternative

crizotinib + timolol ophthalmic

use alternative or monitor BP, HR: combo may incr. risk of bradycardia (additive effects)

• tipranavir
Xalkori (crizotinib)

+

tipranavir

1 interaction

Avoid/Use Alternative

crizotinib + tipranavir

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• tolterodine
Xalkori (crizotinib)

+

tolterodine

1 interaction

Avoid/Use Alternative

crizotinib + tolterodine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tolvaptan
Xalkori (crizotinib)

+

tolvaptan

1 interaction

Avoid/Use Alternative

crizotinib + tolvaptan

HYPONATREMIA USE: avoid combo; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DZ USE: decr. tolvaptan total daily dose by 50% as follows: if taking 60 mg/day, decr. to 15 mg qam and 15 mg qpm; if taking 90 mg/day, decr. to 30 mg qam and 15 mg qpm; if taking 120 mg/day, decr. to 45 mg qam and 15 mg qpm: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metab. inhibited)

• toremifene
Xalkori (crizotinib)

+

toremifene

1 interaction

Avoid/Use Alternative

crizotinib + toremifene

use alternative or monitor ECG, electrolytes: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tramadol
Xalkori (crizotinib)

+

tramadol

1 interaction

Avoid/Use Alternative

crizotinib + tramadol

use alternative or monitor resp. rate, ECG, electrolytes; consider decr. tramadol dose: combo may incr. tramadol and active metabolite levels, risk of CNS and resp. depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite; additive effects)

• trazodone
Xalkori (crizotinib)

+

trazodone

1 interaction

Avoid/Use Alternative

crizotinib + trazodone

use alternative or monitor ECG, BP, electrolytes: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited, additive effects)

• triclabendazole
Xalkori (crizotinib)

+

triclabendazole

1 interaction

Avoid/Use Alternative

crizotinib + triclabendazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Xalkori (crizotinib)

+

trifluridine

1 interaction

Avoid/Use Alternative

crizotinib + trifluridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trimethoprim
Xalkori (crizotinib)

+

trimethoprim

1 interaction

Avoid/Use Alternative

crizotinib + trimethoprim

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (renal transport inhibited, additive effects)

• triptorelin
Xalkori (crizotinib)

+

triptorelin

1 interaction

Avoid/Use Alternative

crizotinib + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Xalkori (crizotinib)

+

tucatinib

1 interaction

Avoid/Use Alternative

crizotinib + tucatinib

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• valbenazine
Xalkori (crizotinib)

+

valbenazine

1 interaction

Avoid/Use Alternative

crizotinib + valbenazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• valganciclovir
Xalkori (crizotinib)

+

valganciclovir

1 interaction

Avoid/Use Alternative

crizotinib + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Xalkori (crizotinib)

+

vandetanib

1 interaction

Avoid/Use Alternative

crizotinib + vandetanib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (renal transport inhibited, additive effects)

• vardenafil
Xalkori (crizotinib)

+

vardenafil

1 interaction

Avoid/Use Alternative

crizotinib + vardenafil

use alternative or monitor ECG, electrolytes, max vardenafil dose 5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited, additive effects)

• vemurafenib
Xalkori (crizotinib)

+

vemurafenib

1 interaction

Avoid/Use Alternative

crizotinib + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• venetoclax
Xalkori (crizotinib)

+

venetoclax

1 interaction

Avoid/Use Alternative

crizotinib + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited)

• venlafaxine
Xalkori (crizotinib)

+

venlafaxine

1 interaction

Avoid/Use Alternative

crizotinib + venlafaxine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• verapamil
Xalkori (crizotinib)

+

verapamil

1 interaction

Avoid/Use Alternative

crizotinib + verapamil

use alternative or monitor ECG, electrolytes, HR, BP, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, AV block, myelosupression, other adverse effects (hepatic metab. inhibited, renal transport inhibited, additive effects)

• vilanterol inhaled
Xalkori (crizotinib)

+

vilanterol inhaled

1 interaction

Avoid/Use Alternative

crizotinib + vilanterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• voclosporin
Xalkori (crizotinib)

+

voclosporin

1 interaction

Avoid/Use Alternative

crizotinib + voclosporin

use alternative or monitor ECG, electrolytes, renal fxn; decr. voclosporin morning dose to 15.8 mg and evening dose to 7.9 mg: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• voriconazole
Xalkori (crizotinib)

+

voriconazole

1 interaction

Avoid/Use Alternative

crizotinib + voriconazole

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• ziprasidone
Xalkori (crizotinib)

+

ziprasidone

1 interaction

Avoid/Use Alternative

crizotinib + ziprasidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)